156 related articles for article (PubMed ID: 19657590)
1. Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women.
Gorai I; Tanaka Y; Hattori S; Iwaoki Y
J Bone Miner Metab; 2010 Mar; 28(2):176-84. PubMed ID: 19657590
[TBL] [Abstract][Full Text] [Related]
2. Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia.
Gorai I; Hattori S; Tanaka Y; Iwaoki Y
J Bone Miner Metab; 2012 May; 30(3):349-58. PubMed ID: 22130786
[TBL] [Abstract][Full Text] [Related]
3. Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis.
Nagatoya K; Nishimoto K; Shibahara N; Takahashi T; Kanehara H; Ueno N; Yasuda H; Okada S; Ueda H; Hirai K; Inoue T;
Clin Exp Nephrol; 2015 Oct; 19(5):939-46. PubMed ID: 25504368
[TBL] [Abstract][Full Text] [Related]
4. Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).
Fujiwara S; Hamaya E; Sato M; Graham-Clarke P; Flynn JA; Burge R
Clin Interv Aging; 2014; 9():1879-93. PubMed ID: 25395843
[TBL] [Abstract][Full Text] [Related]
5. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
6. Adherence to raloxifene therapy: assessment methods and relationship with efficacy.
Finigan J; Naylor K; Paggiosi MA; Peel NF; Eastell R
Osteoporos Int; 2013 Nov; 24(11):2879-86. PubMed ID: 23695420
[TBL] [Abstract][Full Text] [Related]
7. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of combined treatment with raloxifene and alfacalcidol on bone density and biochemical markers of bone turnover in postmenopausal osteoporosis.
Majima T; Komatsu Y; Shimatsu A; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
Endocr J; 2008 Mar; 55(1):127-34. PubMed ID: 18219181
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of alfacalcidol in Chinese postmenopausal women aged over 65 with osteoporosis or osteopenia: An open label, non-comparative, post marketing observational study.
Li N; Jiang Y; He S; Zhao Z; Sun J; Li M; Wang O; Xing X; Xia W
Medicine (Baltimore); 2018 Nov; 97(47):e13159. PubMed ID: 30461612
[TBL] [Abstract][Full Text] [Related]
10. Association between baseline values of bone turnover markers and bone mineral density and their response to raloxifene treatment in Japanese postmenopausal women with osteoporosis.
Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
Endocr J; 2008 Mar; 55(1):41-8. PubMed ID: 18187874
[TBL] [Abstract][Full Text] [Related]
11. Safety of 3-year raloxifene treatment in Japanese postmenopausal women aged 75 years or older with osteoporosis: a postmarketing surveillance study.
Takeuchi Y; Hamaya E; Taketsuna M; Sowa H
Menopause; 2015 Oct; 22(10):1134-7. PubMed ID: 25756692
[TBL] [Abstract][Full Text] [Related]
12. [Postmenopausal osteoporosis. Digital Rx radiogrammetry in the diagnosis and follow-up of treatment with alfacalcidol].
Galeşanu C; Ciubotariu C; Melnic G; Galeşanu MR
Rev Med Chir Soc Med Nat Iasi; 2006; 110(4):833-41. PubMed ID: 17438884
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in Japanese women with postmenopausal osteoporosis treated with raloxifene and vitamin D: post hoc analysis of a postmarketing study.
Ohta H; Hamaya E; Taketsuna M; Sowa H
Curr Med Res Opin; 2015 Jan; 31(1):85-94. PubMed ID: 25299349
[TBL] [Abstract][Full Text] [Related]
14. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women.
Delmas PD; Davis SR; Hensen J; Adami S; van Os S; Nijland EA
Osteoporos Int; 2008 Aug; 19(8):1153-60. PubMed ID: 18256777
[TBL] [Abstract][Full Text] [Related]
15. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
Rosa J; Vanuga P; Payer J; Svobodník A
Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
[TBL] [Abstract][Full Text] [Related]
16. Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04.
Uemura Y; Sone T; Tanaka S; Miyazaki T; Tsukiyama M; Taguchi A; Soen S; Mori S; Hagino H; Sugimoto T; Fukunaga M; Ohta H; Nakamura T; Orimo H; Shiraki M;
Curr Med Res Opin; 2020 Nov; 36(11):1847-1859. PubMed ID: 32870712
[TBL] [Abstract][Full Text] [Related]
17. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial.
Kanis JA; Johnell O; Black DM; Downs RW; Sarkar S; Fuerst T; Secrest RJ; Pavo I
Bone; 2003 Sep; 33(3):293-300. PubMed ID: 13678769
[TBL] [Abstract][Full Text] [Related]
18. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.
Meunier PJ; Vignot E; Garnero P; Confavreux E; Paris E; Liu-Leage S; Sarkar S; Liu T; Wong M; Draper MW
Osteoporos Int; 1999; 10(4):330-6. PubMed ID: 10692984
[TBL] [Abstract][Full Text] [Related]
19. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
[TBL] [Abstract][Full Text] [Related]
20. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
Reginster JY; Lecart MP; Richy F
J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
